Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating a predicted increase of over 20% relative to the benchmark index in the next 12 months [2][7][18]. Core Insights - The company plans to acquire 85% of REGEN Biotech for $190 million, aiming for full ownership within 18 months, which will enhance its indirect stake to 70% [3]. - REGEN Biotech is a leading player in regenerative aesthetics in South Korea, known for its PDLLA injection products, with approvals in 34 countries including China [4]. - The acquisition is expected to create a comprehensive regenerative product matrix, alleviating market concerns about the company's product pipeline [5]. - The Korean factory is anticipated to serve as a global expansion platform, leveraging REGEN Biotech's existing market presence in 34 countries [5]. - The acquisition is projected to significantly boost the company's earnings, with an expected annual profit increase of 30 million yuan based on 2023 data [6]. - The report emphasizes that this acquisition will reshape the company's valuation and address concerns regarding its growth trajectory [7]. Financial Projections - The company’s total revenue is projected to grow from 2,869 million yuan in 2023 to 4,106 million yuan by 2026, reflecting a compound annual growth rate (CAGR) of approximately 18.6% [11][14]. - The net profit attributable to the parent company is expected to rise from 1,858 million yuan in 2023 to 2,730 million yuan in 2026, with a CAGR of about 18.68% [11][14]. - The earnings per share (EPS) is forecasted to increase from 8.60 yuan in 2023 to 9.02 yuan in 2026 [11][14]. - The price-to-earnings (PE) ratio is expected to decrease from 34.22 in 2023 to 22.28 in 2026, indicating a potential valuation re-rating [11][14].

[Table_Main] 公司研究|医疗保健|制药、生物科技与生命科学 证券研究报告 爱美客(300896)公司点评报告 2025 年 03 月 12 日 [Table_Title] 拟收购韩国 REGEN，强化再生医美全球化布局 ——爱美客(300896.SZ)公司事件点评 [Table_Summary] 事件： REGEN Biotech 核心产品在海外市场广受认可，并建立了广泛的分销体 系，渠道优势明显，其国际化业务平台将有助于爱美客产品迅速走向国际市 场，提升海外收入；同时标的公司旗下核心产品 AestheFill 市场表现优异， 有望进一步夯实公司在医美注射填充产品市场的优势，助力盈利能力提升。 投资建议与盈利预测 公司是国内医美上游头部企业，我们预计 2024-2026 年公司实现 EPS 为 6.91/8.31/10.00 元，PE29/24/20x，维持"增持"评级。 风险提示 3 月 10 日爱美客发布公告，拟通过爱美客国际以 1.9 亿美元收购韩国 REGEN Biotech，Inc.85%股份。 点评： 爱美客拟以 1.9 亿美元跨境收购韩国 REGEN，开启国际化战略 爱美客全资子公司 ...

Investment Rating - The report maintains a "Buy" rating for the company, projecting a price increase of over 15% compared to the benchmark index [5][11]. Core Views - The company plans to acquire 85% of REGEN Biotech, Inc. for $190 million, marking a significant step in its international expansion strategy [2][4]. - REGEN Biotech is recognized for its innovative aesthetic products, particularly AestheFill, which has received approval in 34 countries and regions, enhancing the company's market position [3][4]. - The acquisition is expected to strengthen the company's global presence and improve its profitability through enhanced product offerings and distribution channels [4]. Financial Summary - The company is projected to achieve earnings per share (EPS) of 6.91, 8.31, and 10.00 CNY for the years 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 29, 24, and 20 [5][6]. - Revenue is expected to grow from 3,247.22 million CNY in 2024 to 4,750.24 million CNY in 2026, reflecting a compound annual growth rate (CAGR) of approximately 20.84% [6][10]. - The net profit is forecasted to increase from 2,091.91 million CNY in 2024 to 3,028.88 million CNY in 2026, indicating a strong growth trajectory [6][10].